Back to Stocks

LFVN

Lifevantage Corp
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

LifeVantage is currently executing a strategic transition designed to replace volatile, event-driven sales spikes with a sustainable and globally scalable direct-selling model.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

The financial data reveals a concerning trend of contraction across LifeVantage's core metrics. Revenue plunged 25% year-over-year to $43.7 million, largely due to a collapse in sales of the flagship MindBody GLP-1 System.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every LFVN filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The 10-Q filing presents a company at a critical crossroads, balancing aggressive capital return strategies against a backdrop of shrinking organic growth. The tension lies between management's narrative of a 'deliberate pivot' toward sustainability and the hard data showing a significant exodus of active accounts and a decline in flagship product demand. While the reduction in commission percentages suggests improved efficiency, the absolute decline in revenue creates a challenging environment for maintaining operating leverage. Investors are now weighing the impact of the LoveBiome acquisition and the new Evolve Compensation Plan against the reality of a 22% drop in total active accounts. The company's ability to stabilize its consultant base and successfully cross-sell new product stacks will determine if the current buybacks are a prudent use of capital or a cosmetic distraction from a deteriorating core business. The upcoming quarters will be decisive in proving whether the transition to a 'stack-driven' model can arrest the current revenue slide.

Selected Quarter

Core Takeaway

LifeVantage is trading top-line growth for operational efficiency and shareholder returns, but a steep decline in active accounts threatens long-term viability.

Investor Lens

The trade-off is between a disciplined, shrinking company returning cash and a growth company losing its customer base.

Watch Next

Quarterly active account trends and the integration success of LoveBiome revenue.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.08Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 6

Revenue declined 25% year-over-year due to falling GLP-1 system sales.

earnings miss
80%
bullishMay 6

Implementation of a $60 million share repurchase program to support stock value.

buyback
70%
bullishMay 6

Commission expenses as a percentage of revenue decreased from 45.6% to 42.5%.

margin expansion
40%
neutralMay 6

Acquisition of LoveBiome assets to diversify into gut health microbiome care.

acquisition
50%
bearishMay 6

Revenue declined 25% year-over-year due to falling GLP-1 system sales.

earnings miss
80%
bullishMay 6

Implementation of a $60 million share repurchase program to support stock value.

buyback
70%
bullishMay 6

Commission expenses as a percentage of revenue decreased from 45.6% to 42.5%.

margin expansion
40%
neutralMay 6

Acquisition of LoveBiome assets to diversify into gut health microbiome care.

acquisition
50%
bearishMay 6

Revenue declined 25% year-over-year due to falling GLP-1 system sales.

earnings miss
80%
bullishMay 6

Implementation of a $60 million share repurchase program to support stock value.

buyback
70%
bullishMay 6

Commission expenses as a percentage of revenue decreased from 45.6% to 42.5%.

margin expansion
40%
neutralMay 6

Acquisition of LoveBiome assets to diversify into gut health microbiome care.

acquisition
50%
bearishMay 6

Revenue declined 25% year-over-year due to falling GLP-1 system sales.

earnings miss
80%
bullishMay 6

Implementation of a $60 million share repurchase program to support stock value.

buyback
70%
bullishMay 6

Commission expenses as a percentage of revenue decreased from 45.6% to 42.5%.

margin expansion
40%
neutralMay 6

Acquisition of LoveBiome assets to diversify into gut health microbiome care.

acquisition
50%
bearishMay 6

Revenue declined 25% year-over-year due to falling GLP-1 system sales.

earnings miss
80%
bullishMay 6

Implementation of a $60 million share repurchase program to support stock value.

buyback
70%
bullishMay 6

Commission expenses as a percentage of revenue decreased from 45.6% to 42.5%.

margin expansion
40%
neutralMay 6

Acquisition of LoveBiome assets to diversify into gut health microbiome care.

acquisition
50%
bearishMay 6

Revenue declined 25% year-over-year due to falling GLP-1 system sales.

earnings miss
80%
bullishMay 6

Implementation of a $60 million share repurchase program to support stock value.

buyback
70%
bullishMay 6

Commission expenses as a percentage of revenue decreased from 45.6% to 42.5%.

margin expansion
40%
neutralMay 6

Acquisition of LoveBiome assets to diversify into gut health microbiome care.

acquisition
50%
bearishMay 6

Revenue declined 25% year-over-year due to falling GLP-1 system sales.

earnings miss
80%
bullishMay 6

Implementation of a $60 million share repurchase program to support stock value.

buyback
70%
bullishMay 6

Commission expenses as a percentage of revenue decreased from 45.6% to 42.5%.

margin expansion
40%
neutralMay 6

Acquisition of LoveBiome assets to diversify into gut health microbiome care.

acquisition
50%

Filing History

10-QMay 6, 2026
Expand Sequence

The 10-Q filing presents a company at a critical crossroads, balancing aggressive capital return strategies against a backdrop of shrinking organic growth. The tension lies between management's narrative of a 'deliberate pivot' toward sustainability and the hard data showing a significant exodus of active accounts and a decline in flagship product demand. While the reduction in commission percentages suggests improved efficiency, the absolute decline in revenue creates a challenging environment for maintaining operating leverage. Investors are now weighing the impact of the LoveBiome acquisition and the new Evolve Compensation Plan against the reality of a 22% drop in total active accounts. The company's ability to stabilize its consultant base and successfully cross-sell new product stacks will determine if the current buybacks are a prudent use of capital or a cosmetic distraction from a deteriorating core business. The upcoming quarters will be decisive in proving whether the transition to a 'stack-driven' model can arrest the current revenue slide.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.